Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer

JAMA Oncology

Volumn 2, Issue 11, 2016, Pages 1441-1449

  Scher, Howard I ^a,b   Lu, David ^c   Schreiber, Nicole A ^a   Louw, Jessica ^c   Graf, Ryon P ^c   Vargas, Hebert A ^a,b   Johnson, Ann ^c   Jendrisak, Adam ^c   Bambury, Richard ^a,d   Danila, Daniel ^a,b   McLaughlin, Brigit ^a   Wahl, Justin ^c   Greene, Stephanie B ^c   Heller, Glenn ^a   Marrinucci, Dena ^c   Fleisher, Martin ^a   Dittamore, Ryan ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Epic Sciences Inc   (United States)

^d University College Cork   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; ISOPROTEIN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TAXOID; TUMOR MARKER;

AGED; BLOOD; CROSS-SECTIONAL STUDY; DISEASE COURSE; DRUG RESISTANCE; GENETICS; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR EMBOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; SENSITIVITY AND SPECIFICITY; TAXOIDS; TREATMENT OUTCOME;

EID: 85013127577     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.1828     Document Type: Article

References (27)

1. Lissbrant IF, Garmo H, Widmark A, Stattin P. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013;52(8):1593-1601.
2. Templeton AJ, Vera-Badillo FE, Wang L, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol. 2013;24(12):2972-2977.
3. Schrader AJ, Boegemann M, Ohlmann CH, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol. 2014;65(1):30-36.
4. Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical TrialsWorking Group 3 [published online February 22, 2016]. J Clin Oncol. doi:10.1200/jco.2015.64.2702.
5. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol. 2014;11(3):129-144.
6. Scher HI, Morris MJ, Larson S, Heller G. Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol. 2013;10(4): 225-234.
7. Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2014;7(1):1-11.
8. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73(2):483-489.
9. Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer. 2014;21(4): T87-T103.
10. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11): 1028-1038.
11. Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1(5):582-591.
12. OnstenkW, Sieuwerts AM, Kraan J, et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol. 2015;68 (6):939-945.
13. Antonarakis ES. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key? Expert Rev Anticancer Ther. 2015;15(2):143-145.
14. Maughan BL, Antonarakis ES. Clinical relevance of androgen receptor splice variants in castration-resistant prostate cancer. Curr Treat Options Oncol. 2015;16(12):57.
15. Marrinucci D, Bethel K, Kolatkar A, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012;9(1): 016003.
16. Werner SL, Graf RP, Landers ML, et al. Analytical validation and capabilities of the Epic CTC platform: Enrichment-free circulating tumour cell detection and characterization. J Circulating Biomarkers. 2015;4(3). doi:10.5772/60725.
17. Scher HI, Halabi S, Tannock I, et al; Prostate Cancer Clinical TrialsWorking Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical TrialsWorking Group. J Clin Oncol. 2008;26(7):1148-1159.
18. Pond GR, Armstrong AJ, Wood BA, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol. 2012; 61(2):363-369.
19. Punnoose EA, Ferraldeschi R, Szafer-Glusman E, et al. PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. Br J Cancer. 2015;113(8):1225-1233.
20. Watson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A. 2010;107(39):16759-16765.
21. Sun F, Chen HG, LiW, et al. Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem. 2014;289(3):1529-1539.
22. Efstathiou E, Titus M, Wen S, et al. Molecular characterization of enzalutamide-Treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015;67(1):53-60.
23. Qu Y, Dai B, Ye D, et al. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep. 2015;5:7654.
24. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J AmStat Assoc. 1989; 84(408):1074-1078.
25. Nakazawa M, Lu C, Chen Y, et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol. 2015;26(9): 1859-1865.
26. Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Circulating tumor cells: A multifunctional biomarker. Clin Cancer Res. 2014; 20(10):2553-2568.
27. Guo Z, Yang X, Sun F, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69(6):2305-2313.